M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
The fund funneled around $16 million (€14 million) into the startups to support research into antibiotics and prophylactic vaccines.
A connection between TDP-43, which has been implicated in ALS, and another gene could yield new approaches to treating the disease.
CMO Sean Bohen and I-O head David Berman are leaving AstraZeneca, while Roche's Omar Khwaja and Pearl Huang land at new biotechs.
Celgene ended the week by expanding its CAR-T toolkit via a deal with Obsidian and placing an $80 million bet on Kyn.
A few days after leaving Insmed to take up an “employment opportunity on the West Coast”, Paul Streck has popped up at migraine specialist Alder.
The collaboration will analyze MRI data from 35,000 multiple sclerosis patients and results from IL-17 inhibitor trials.
Apple and J&J are teaming up to see if the Apple Watch can help catch and diagnose seniors with atrial fibrillation earlier and faster than before.
A University of Chicago teams has shown that a derivative of the hypertension drug Wytensin can protect myelin in animal models of multiple sclerosis.
Alzheimer’s drug developer Alzheon has pulled plans for a public listing on the Nasdaq for the second time in nine months.
Shares in the nanocap biotech shot up more than 100% in premarket trading before falling away somewhat as people dug deeper into the data.
